Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
30 June 2020 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434…
Acrux announces co-development agreement with Amring Pharmaceuticals Inc
2 July 2020 Acrux Limited a commercial-stage pharmaceutical company focused on developing generic topical drug products is pleased to announce that it has entered into an exclusive development and commercialisation agreement with Amring Pharmaceuticals, Inc. in the United…
Almac Group Launches Tempod 1000 to Improve Clinical Site Temperature Data Management
24 June 2020 Almac Clinical Services, part of the Almac Group, the global contract pharmaceutical development and manufacturing organization, has launched Tempod® 1000 which bolsters the company’s Site Compliance and temperature management offering for sponsors. An extension to Almac’s…
New c-FIND test accurately diagnoses infection in minutes
1 July 2020 Walter and Eliza Hall Institute researchers have developed a fast, new test for infections and infectious diseases that could transform Australia’s ability to provide targeted clinical care and respond to pandemics and biosecurity threats. Called…
Phillips Ormonde Fitzpatrick reappointed to IP panel for CSIRO
1 July 2020 The Phillips Ormonde Fitzpatrick (POF) Group are pleased to announce reappointment as a preferred IP provider for CSIRO, Australia’s leading national science and technology organisation. POF has worked with CSIRO for over 40 years and…
Investment In Artificial Intelligence Is Real Deal For Victoria
26 June 2020 The Victorian Government today announced it would contribute $1.5 million to the establishment of Australia’s first multimillion-dollar accelerator and investment fund for Artificial Intelligence (AI) scaleups. Backed by LaunchVic, Victoria’s startup agency, Boab AI in…
Immutep Completes Recruitment For Part A Of Phase II TACTI-002 Study
29 June 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has enrolled and safely dosed the last patient for stage 2 of Part A (1st line…
New Real-World Data from Medtronic Global SYMPLICITY Registry Show Renal Denervation Lowered Blood Pressure in Hypertension Patients
25 June 2020 Medtronic plc, the global leader in medical technology, today reported new data from the Global SYMPLICITY Registry (GSR), which showed that renal denervation (RDN) with the Medtronic Symplicity™ Renal Denervation System significantly reduced blood pressure…
RMIT, Siemens and Festo partner to create new Industrial Digital Innovation Hub
25 June 2020 RMIT, Siemens and Festo have signed a strategic Memorandum of Understanding (MoU) to explore major areas of cooperation to help drive workforce transformation for Industry 4.0 in the Australasian region, including the establishment of an…
Sienna Diagnostics Calls Notting Hill Home
26 June 2020 Sienna relocates to 23 Normanby Road, Notting Hill. Sienna leaves the STC precinct after a successful 5 years. Development, commercialisation and launch of the hTERT IVD in the USA (2016) Successful registrations and l istings…
Planet Innovation wins global manufacturing contract for decontamination products used worldwide for infectious disease control
26 June 2020 TOMI Environmental Solutions, a global company specializing in decontamination and disinfection, has selected Planet Innovation, a healthtech innovation and commercialization company, to manufacture its SteraMist® range of products used worldwide for infectious disease control, including…
CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
24 June 2020 Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure (NASDAQ:…
